irinotecan has been researched along with Body Weight in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (12.82) | 18.2507 |
| 2000's | 19 (48.72) | 29.6817 |
| 2010's | 12 (30.77) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Dahlgren, D; Hellström, PM; Kullenberg, F; Lennernäs, H; Nygren, P; Peters, K; Rosenqvist, E; Sjöblom, M | 1 |
| Chawla, SP; Higuchi, T; Hoffman, RM; Hu, K; Kawaguchi, K; Kiyuna, T; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Cheng, Y; Fu, C; Hu, Y; Wang, D; Wu, Y; Yang, X; Yang, Y; Zhang, J | 1 |
| Brčić Karačonji, I; Čanović, S; Fuchs, N; Jurič, A; Kopjar, N; Lucić Vrdoljak, A; Micek, V; Mikolić, A; Mršić, G; Neuberg, M; Prester, L; Žunec, S | 1 |
| Gao, S; Ghose, R; Hu, M; Ittmann, MM; Mallick, P; Shah, P; Trivedi, M | 1 |
| Bossevot-Desmaris, R; Bouchahda, M; Haydar, M; Innominato, P; Karaboué, A; Komarzynski, S; Lévi, F; Mocquery, M; Plessis, V; Ulusakarya, A | 1 |
| Berland, E; Filipski, E; Guettier, C; Lévi, F; Okyar, A; Ozturk, N; van der Horst, GT | 1 |
| Bateman, E; Keefe, D; Klein, G; Mayo, B; Plews, E; Weaver, E; White, I; Wignall, A; Wozniak, B | 1 |
| Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T | 1 |
| Alvarenga, EM; Araújo, AR; Araújo, TS; de C Brito, GA; Martins, CS; Medeiros, JV; Nogueira, KM; Pacífico, DM; Sousa, DP; Sousa, FB; Souza, EP; Souza, LK | 1 |
| Miya, T; Morimoto, Y; Ooi, K; Sasaki, H | 1 |
| Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Le Roy, S; Sawyer, MB; Xue, H | 1 |
| Ahlawat, P; Srinivas, NR | 1 |
| Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z | 1 |
| Brundage, RC; Gaber, MW; Hanna, SK; Khatri, A; Kirstein, MN; Naimark, MD; Stewart, CF | 1 |
| Ikeda, R; Iseki, K; Iwashita, Y; Kondo, T; Osada, T; Shibayama, Y; Sugawara, M; Takeda, Y; Yamada, K; Yoshikawa, Y | 1 |
| Albertsson, P; Lennernäs, B; Norrby, K | 1 |
| Kawabe, Y; Mori, N; Murakami, T; Yokooji, T | 1 |
| Akagi, T; Higuchi, S; Inoue, K; Ishizaki, T; Kage, Y; Makinosumi, T; Ohdo, S; Taguchi, Y; Ushinohama, K; Yamauchi, A; Yukawa, E | 1 |
| Hashimoto, S; Kado, S; Kaneda, N; Kurita, A; Onoue, M; Yokokura, T | 1 |
| LaBell, R; Lansdown, R; Ramaswami, R; Romanowski, M; Sweitzer, R; Unger, E; Williams, J | 1 |
| Fujita, F; Fujita, M; Fujiwara, T; Kakushima, M; Kawaguchi, T; Kiuchi, S; Koike, M; Kudoh, S; Okuno, S; Sakamoto, Y; Yano, S; Yano, T | 1 |
| Cheshire, PJ; Danks, MK; Houghton, PJ; Hyatt, JL; Iacono, L; Morton, CL; Potter, PM; Stewart, CF; Taylor, KR | 1 |
| Chan, E; Chan, SY; Chen, X; Duan, W; Ho, PC; Hu, Z; Huang, M; Li, X; Xu, C; Yang, H; Yang, X; Zhou, S; Zhu, YZ | 1 |
| El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V | 1 |
| Alvarez, E; Bowen, JM; Burns, J; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Alvarez, E; Bowen, JM; Finnie, J; Gibson, RJ; Keefe, DM | 1 |
| Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
| Abderrahim, AG; Bressolle, FM; Duffour, J; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Itoh, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Morino, H; Nakagawa, K; Negoro, S; Takada, M; Takifuji, N | 1 |
| Hayakawa, T; Kamataki, T; Kase, Y; Togashi, Y | 1 |
| Hirota, S; Hirotsu, S; Sadzuka, Y | 1 |
| Hashimoto, A; Matsuura, T; Murakami, K; Saiki, I; Sakukawa, R; Sano, M; Yamada, Y; Yonekura, K | 1 |
| Hasegawa, S; Ishikawa, H; Kamma, H; Ohtomo, M; Ohtsuka, M; Satoh, H | 1 |
| Bissery, MC; D'Attino, RM; Filipski, E; Garufi, C; Granda, TG; Lévi, F; Terzoli, E; Vrignaud, P | 1 |
| Morales, C; Vaquero, J; Zurita, M | 1 |
| Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
39 other study(ies) available for irinotecan and Body Weight
| Article | Year |
|---|---|
Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Diarrhea; Doxorubicin; Fluorouracil; Idarubicin; Intestinal Mucosa; Irinotecan; Male; Methotrexate; Mucositis; Rats; Rats, Wistar | 2022 |
A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Body Weight; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Liver Neoplasms, Experimental; Mice, Nude; Phenylurea Compounds; Proof of Concept Study; Pyridines; Xenograft Model Antitumor Assays | 2020 |
Mechanisms of Gegen Qinlian Pill to ameliorate irinotecan-induced diarrhea investigated by the combination of serum pharmacochemistry and network pharmacology.
Topics: Animals; Body Weight; Diarrhea; Disease Models, Animal; Drugs, Chinese Herbal; Gastrointestinal Diseases; Gene Expression Regulation; Heme Oxygenase-1; Inflammation; Intestines; Irinotecan; Kelch-Like ECH-Associated Protein 1; Membrane Proteins; Metabolic Networks and Pathways; Mice; NF-E2-Related Factor 2; Oxidative Stress; Protective Agents; Tablets | 2021 |
Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Body Weight; Camptothecin; DNA Damage; Dose-Response Relationship, Drug; Dronabinol; Irinotecan; Liver; Liver Function Tests; Male; Mutagenicity Tests; Organ Size; Oxidative Stress; Rats, Wistar | 2018 |
Impact of diet on irinotecan toxicity in mice.
Topics: Animals; Body Weight; Camptothecin; Carboxylesterase; Diarrhea; Diet; Fatty Liver; Glucuronidase; Irinotecan; Male; Metabolome; Mice, Inbred C57BL; Toxicity Tests | 2018 |
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Circadian Rhythm; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Patient Reported Outcome Measures; Patient-Centered Care; Pilot Projects; Sleep; Survival Analysis; Telemedicine; User-Computer Interface | 2018 |
Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Camptothecin; Cell Line, Tumor; Chronotherapy; Circadian Rhythm; Cyclosporins; Endpoint Determination; Female; Ileum; Irinotecan; Mice; Mucous Membrane; Osteosarcoma; RNA, Messenger; Time Factors | 2014 |
Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Blood Proteins; Body Weight; Camptothecin; Cattle; Colitis; Diarrhea; Enteritis; Female; Immunoglobulins; Injections, Intraperitoneal; Irinotecan; Jejunal Diseases; Mucositis; Random Allocation; Rats | 2016 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cholera Toxin; Colon; Contrast Media; Diarrhea; Fluorouracil; Gastrointestinal Diseases; Haptoglobins; Intestinal Mucosa; Iohexol; Irinotecan; Jejunum; Male; Organoplatinum Compounds; Oxaliplatin; Permeability; Protein Precursors; Rats; Rats, Sprague-Dawley | 2016 |
Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.
Topics: Animals; Antioxidants; Body Weight; Camptothecin; Cyclooxygenase 2; Cymenes; Female; Immunohistochemistry; Inflammation; Intestines; Irinotecan; Leukocyte Count; Mice; Molecular Docking Simulation; Monoterpenes; Mucositis; NF-kappa B; Oxidative Stress; Peroxidase; Survival Analysis; Transient Receptor Potential Channels; TRPA1 Cation Channel | 2016 |
[Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats].
Topics: Administration, Oral; Animals; Body Weight; Camptothecin; Diarrhea; Feeding Behavior; Irinotecan; Lacticaseibacillus casei; Male; Rats; Rats, Wistar; Time Factors | 2008 |
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays | 2008 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Dietary Supplements; Fatty Acids, Omega-3; Female; Fluorouracil; Glutamine; Immune Tolerance; Irinotecan; Leukocyte Count; Nutritional Status; Rats; Rats, Inbred F344; Treatment Failure; Xenograft Model Antitumor Assays | 2009 |
Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Humans; Irinotecan; Macaca mulatta; Mice; Models, Statistical; Nonlinear Dynamics; Rats; Species Specificity; Topoisomerase I Inhibitors | 2009 |
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Body Weight; Brain; Camptothecin; Dose-Response Relationship, Radiation; Half-Life; Irinotecan; Male; Models, Statistical; Nonlinear Dynamics; Rats; Rats, Sprague-Dawley | 2011 |
Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.
Topics: Animals; ATP-Binding Cassette Transporters; Base Sequence; Body Weight; Camptothecin; Cell Line; DNA Primers; Fluorouracil; Humans; Intestinal Absorption; Irinotecan; Male; Phosphorylation; Polymerase Chain Reaction; Proto-Oncogene Proteins c-jun; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger | 2011 |
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.
Topics: Animals; Body Weight; Camptothecin; Endothelial Cells; Irinotecan; Male; Mesentery; Mitoxantrone; Neovascularization, Pathologic; Neovascularization, Physiologic; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Topoisomerase Inhibitors; Vascular Endothelial Growth Factor A | 2012 |
Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Topics: Alkaline Phosphatase; Animals; Biliary Tract; Body Weight; Camptothecin; Diarrhea; Drug Interactions; Genistein; Glucuronates; Glucuronides; Intestinal Mucosa; Intestines; Irinotecan; Kidney; Liver; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Probenecid; Rats; Rats, Sprague-Dawley | 2013 |
Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; Camptothecin; Cell Cycle; DNA; Esterases; Hydroxyurea; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Sarcoma 180 | 2003 |
Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Diseases; Camptothecin; Diarrhea; Infusions, Intravenous; Intestines; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 2003 |
Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Drug Delivery Systems; Enzyme Inhibitors; Half-Life; HT29 Cells; Humans; Injections, Intravenous; Irinotecan; Lactones; Light; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Particle Size; Scattering, Radiation; Serum Albumin; Topoisomerase Inhibitors | 2003 |
MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Body Weight; Camptothecin; Cell Line, Tumor; Dextrans; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Time Factors; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Dose-Response Relationship, Drug; Esterases; Gastrointestinal Tract; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Transplantation; Rhabdomyosarcoma; Sarcoma, Experimental | 2005 |
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Body Weight; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Interactions; Half-Life; Hypericum; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Female; Fluorouracil; Galanin; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Serotonin; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Diarrhea; Fibroblast Growth Factors; Gastroenteritis; Irinotecan; Mucositis; Rats; Rats, Inbred Strains | 2007 |
Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
Topics: Animals; Body Weight; Camptothecin; Diarrhea; Disease Models, Animal; Female; Irinotecan; Mucositis; Neoplasm Transplantation; Organ Size; Rats; Survival Rate | 2007 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Body Surface Area; Body Weight; Camptothecin; Digestive System Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Reproducibility of Results | 2007 |
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Humans; Injections, Intraperitoneal; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1993 |
Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colon; Diarrhea; Dinoprostone; Enzyme Inhibitors; Intestinal Absorption; Intestine, Large; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water | 1997 |
Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile; Body Weight; Camptothecin; Carcinoma, Ehrlich Tumor; Drug Carriers; Feces; Irinotecan; Liposomes; Liver; Male; Mice; Neoplasm Transplantation; Water | 1998 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight; Camptothecin; Carcinoma, Hepatocellular; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Specific Pathogen-Free Organisms; Survival Rate; Trimethylsilyl Compounds; Tumor Cells, Cultured | 1998 |
Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Carcinoma, Large Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Neoplasm Transplantation; Rats; Sarcoma, Yoshida; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |
Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Camptothecin; Drug Administration Schedule; Irinotecan; Male; Mice; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin | 2002 |
Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cell Division; Irinotecan; Neuroectodermal Tumors; Rats; Rats, Wistar; Time Factors | 2002 |
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |